LifePoint, Inc. to Present at European BioInvestor Forum

- Webcast European Investor Presentation to Support

Berlin Stock Exchange Listing -



Apr 30, 2001, 01:00 ET from LifePoint, Inc.

    ONTARIO, Calif., April 30 /PRNewswire/ -- LifePoint, Inc. (Amex:   LFP)
 today announced that Linda H. Masterson, President and Chief Executive
 Officer, will present at the Noonan/Russo BioInvestor Forum on Friday,
 May 4, 2001 at 08:40 Greenwich Mean Time (04:40 Eastern Time) in the Arabella
 Sheraton Grand Hotel in Frankfurt, Germany. LifePoint, already listed on the
 Berlin Stock Exchange (BSE: LP6), plans to further grow its European market
 potential by presenting its Impact(TM) Test System and international business
 growth strategy.
     The BioInvestor Forum is a unique event providing six presenting companies
 an intimate environment with a select group of top-level European investors
 and media personnel.  The Forum will cover medical devices, biotechnology and
 pharmaceuticals in the current and future European market.  The Forum will be
 webcast live on the Noonan/Russo website at http://www.noonanrusso.com , and
 LifePoint's presentation will be archived subsequently on its website at
 http://www.lifepointinc.com .
     "The chance to meet with European investors face-to-face and share
 information on LifePoint's progress and global goals is very exciting," stated
 Ms. Masterson. "In the global market, the Impact Test System will achieve
 market dominance because its advantages over current technology are clear: law
 enforcement and industry officials will save lives and money with this rapid
 and cost-effective method for non-invasive detection of substances of abuse.
 We aim to aggressively expand into international markets following our product
 launch at the end of the second quarter 2001."
 
     About LifePoint, Inc.
     LifePoint, Inc. is a medical technology company designing the Impact Test
 System -- a rapid diagnostic testing, screening, and therapeutic drug
 monitoring device for use in the workplace, home health care, ambulances,
 pharmacies and law enforcement. LifePoint is focused on the commercialization
 of the flow immunosensor technology licensed from the Naval Research
 Laboratories. This patented technology, when used in conjunction with
 LifePoint's own patented and proprietary technologies using saliva as a
 non-invasive test specimen, has allowed for the development of a broadly
 applicable non-invasive, rapid, on-site diagnostic test system.  The first
 product being commercialized is for the simultaneous detection of drugs of
 abuse and alcohol, estimated to be over a $1.6 billion market by 2002.
 
     This press release contains forward-looking statements regarding future
 events and the future performance of LifePoint, Inc. that involve risks and
 uncertainties that could cause actual results to differ materially. These
 risks include, but are not limited to, the completion of product
 commercialization, the need for additional funding, satisfactory results from
 clinical trials, dependence on third parties for clinical testing and
 marketing, and market acceptance. These risks are described in further detail
 in the Company's reports filed with the Securities and Exchange Commission.
 
     LifePoint(TM) and Impact(TM) are trademarks of LifePoint, Inc.
 
     Contact:  Linda H. Masterson, CEO & President of LifePoint, Inc.,
 909-418-3000 ext. 400, lifepoint@LFPT.com; or Brian Maude of Noonan-Russo
 Communications, Inc., 415-677-4455 ext. 360, b.maude@noonarusso.com, for
 LifePoint.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X27434709
 
 

SOURCE LifePoint, Inc.
    ONTARIO, Calif., April 30 /PRNewswire/ -- LifePoint, Inc. (Amex:   LFP)
 today announced that Linda H. Masterson, President and Chief Executive
 Officer, will present at the Noonan/Russo BioInvestor Forum on Friday,
 May 4, 2001 at 08:40 Greenwich Mean Time (04:40 Eastern Time) in the Arabella
 Sheraton Grand Hotel in Frankfurt, Germany. LifePoint, already listed on the
 Berlin Stock Exchange (BSE: LP6), plans to further grow its European market
 potential by presenting its Impact(TM) Test System and international business
 growth strategy.
     The BioInvestor Forum is a unique event providing six presenting companies
 an intimate environment with a select group of top-level European investors
 and media personnel.  The Forum will cover medical devices, biotechnology and
 pharmaceuticals in the current and future European market.  The Forum will be
 webcast live on the Noonan/Russo website at http://www.noonanrusso.com , and
 LifePoint's presentation will be archived subsequently on its website at
 http://www.lifepointinc.com .
     "The chance to meet with European investors face-to-face and share
 information on LifePoint's progress and global goals is very exciting," stated
 Ms. Masterson. "In the global market, the Impact Test System will achieve
 market dominance because its advantages over current technology are clear: law
 enforcement and industry officials will save lives and money with this rapid
 and cost-effective method for non-invasive detection of substances of abuse.
 We aim to aggressively expand into international markets following our product
 launch at the end of the second quarter 2001."
 
     About LifePoint, Inc.
     LifePoint, Inc. is a medical technology company designing the Impact Test
 System -- a rapid diagnostic testing, screening, and therapeutic drug
 monitoring device for use in the workplace, home health care, ambulances,
 pharmacies and law enforcement. LifePoint is focused on the commercialization
 of the flow immunosensor technology licensed from the Naval Research
 Laboratories. This patented technology, when used in conjunction with
 LifePoint's own patented and proprietary technologies using saliva as a
 non-invasive test specimen, has allowed for the development of a broadly
 applicable non-invasive, rapid, on-site diagnostic test system.  The first
 product being commercialized is for the simultaneous detection of drugs of
 abuse and alcohol, estimated to be over a $1.6 billion market by 2002.
 
     This press release contains forward-looking statements regarding future
 events and the future performance of LifePoint, Inc. that involve risks and
 uncertainties that could cause actual results to differ materially. These
 risks include, but are not limited to, the completion of product
 commercialization, the need for additional funding, satisfactory results from
 clinical trials, dependence on third parties for clinical testing and
 marketing, and market acceptance. These risks are described in further detail
 in the Company's reports filed with the Securities and Exchange Commission.
 
     LifePoint(TM) and Impact(TM) are trademarks of LifePoint, Inc.
 
     Contact:  Linda H. Masterson, CEO & President of LifePoint, Inc.,
 909-418-3000 ext. 400, lifepoint@LFPT.com; or Brian Maude of Noonan-Russo
 Communications, Inc., 415-677-4455 ext. 360, b.maude@noonarusso.com, for
 LifePoint.
 
                     MAKE YOUR OPINION COUNT -- Click Here
                http://tbutton.prnewswire.com/prn/11690X27434709
 
 SOURCE  LifePoint, Inc.